References
- 1. NDISANG JF., VANNACCI A., RASTOGI S. Insulin resistance, type 1 and type 2 diabetes, and related complications 2017. J Diabetes Res. 2017; 2017:1478294.
- 2. TAYLOR R. Insulin resistance and type 2 diabetes. Diabetes. 2012; 61(4):778–9.
- 3. NICKERSON HD., DUTTA S. Diabetic complications: current challenges and opportunities. J Cardiovasc Transl Res. 2012; 5(4):375–9.
- 4. PAPATHEODOROU K., BANACH M., BEKIARI E., RIZZO M., EDMONDS M. Complications of diabetes 2017. J Diabetes Res. 2018; 2018:3086167.
- 5. SHAN PF., LI Q., KHAMAISI M., QIANG GF. Type 2 Diabetes mellitus and macrovascular complications. Int J Endocrinol. 2017; 2017:4301461.
- 6. JING X., CHEN J., DONG Y., HAN D., ZHAO H., WANG X., et al. Related factors of quality of life of type 2 diabetes patients: a systematic review and meta-analysis. Health Qual Life Outcomes. 2018; 16(1):189.
- 7. TRIKKALINOU A., PAPAZAFIROPOULOU AK., MELIDONIS A. Type 2 diabetes and quality of life. World J Diabetes. 2017; 8(4):120–9.
- 8. WOU C., UNWIN N., HUANG Y., ROGLIC G. Implications of the growing burden of diabetes for premature cardiovascular disease mortality and the attainment of the Sustainable Development Goal target 3.4. Cardiovasc Diagn Ther. 2019; 9(2):140–9.
- 9. GBD 2017 DISEASE AND INJURY INCIDENCE AND PREVALENCE COLLABORATORS. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1789–858.
- 10. INTERNATIONAL DIABETES FEDERATION. IDF Diabetes Atlas. 9 ed, 2019.
- 11. GBD 2017 CAUSES OF DEATH COLLABORATORS. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1736–88.
- 12. KHAN MAB., HASHIM MJ., KING JK., GOVENDER RD., MUSTAFA H., Al KAABI J. Epidemiology of type 2 diabetes – global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020; 10(1):107–11.
- 13. SEURING T., ARCHANGELIDI O., SUHRCKE M. The economic costs of type 2 diabetes: a global systematic review. Pharmacoeconomics. 2015; 33(8):811–31.
- 14. MARIN-PENALVER JJ., MARTIN-TIMON I., SEVILLANO-COLLANTES C., DEL CANIZO-GOMEZ FJ. Update on the treatment of type 2 diabetes mellitus. World J Diabetes. 2016; 7(17):354–95.
- 15. INZUCCHI SE., BERGENSTAL RM., BUSE JB., DIAMANT M., FERRANNINI E., NAUCK M., et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015; 38(1):140–9.
- 16. CHAUDHURY A., DUVOOR C., REDDY DENDI VS., KRALETI S., CHADA A., RAVILLA R., et al. Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front Endocrinol (Lausanne). 2017; 8:6.
- 17. TRAN L., ZIELINSKI A., ROACH AH., JENDE JA., HOUSEHOLDER AM., COLE EE., et al. Pharmacologic treatment of type 2 diabetes: oral medications. Ann Pharmacother. 2015; 49(5):540–56.
- 18. LEE BW., KIM JH., KO SH., HUR KY., KIM NH., RHEE SY., et al. Insulin therapy for adult patients with type 2 diabetes mellitus: a position statement of the Korean Diabetes Association, 2017. Diabetes Metab J. 2017; 41(5):367–73.
- 19. LARKIN ME., CAPASSO VA., CHEN CL., MAHONEY EK., HAZARD B., CAGLIERO E., et al. Measuring psychological insulin resistance: barriers to insulin use. Diabetes Educ. 2008; 34(3):511–7.
- 20. POLONSKY WH., FISHER L., GUZMAN S., VILLA-CABALLERO L., EDELMAN SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005; 28(10):2543–5.
- 21. SONG Y., KU BJ., CHO J., JUN Y., KIM B., NAM S. The prevalence of insulin refusal and psychological insulin resistance among Korean patients with type 2 diabetes mellitus. Ann Transl Med. 2019; 7(23):760.
- 22. TAN WL., ASAHAR SF., HARUN NL. Insulin therapy refusal among type II diabetes mellitus patients in Kubang Pasu district, the state of Kedah, Malaysia. Singapore Med J. 2015; 56(4):224–7.
- 23. WOUDENBERG YJ., LUCAS C., LATOUR C., SCHOLTE OP REIMER WJ. Acceptance of insulin therapy: a long shot? Psychological insulin resistance in primary care. Diabet Med. 2012; 29(6):796–802.
- 24. NG CJ., LAI PS., LEE YK., AZMI SA., TEO CH. Barriers and facilitators to starting insulin in patients with type 2 diabetes: a systematic review. Int J Clin Pract. 2015; 69(10):1050–70.
- 25. NGAMJARUS C., CHONGSUVIVATWONG V., McNEIL E. n4Studies: sample size calculation for an epidemiological study on a smart device. Siriraj Med J. 2016; 68:160–70.
- 26. ABU HASSAN H., TOHID H., MOHD AMIN R., LONG BIDIN MB., MUTHUPALANIAPPEN L., OMAR K. Factors influencing insulin acceptance among type 2 diabetes mellitus patients in a primary care clinic: a qualitative exploration. BMC Fam Pract. 2013; 14:164.
- 27. BANERJEE A., CHITNIS UB., JADHAV SL., BHAWALKER JS., CHAUDHURY S. Hypothesis testing, type I and type II errors. Ind Psychiatry J. 2009; 18(2):127–31.
- 28. BIN RSHEED A., CHENOWETH I. Barriers that practitioners face when initiating insulin therapy in general practice settings and how they can be overcome. World J Diabetes. 2017; 8(1):28–39.
- 29. KABADI UM. Starting insulin in type 2 diabetes: overcoming barriers to insulin therapy. Int J Diabetes Dev Ctries. 2008; 28(2):65–8.
- 30. RUSSELL-JONES D., POUWER F., KHUNTI K. Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes Obes Metab. 2018; 20(3):488–96.
- 31. ALLEN NA., ZAGARINS SE., FEINBERG RG., WELCH G.. Treating psychological insulin resistance in type 2 diabetes. J Clin Transl Endocrinol. 2016; 7:1–6.
- 32. KAPOOR U., RAMASAMY G., SELVARAJ K., SAHOO JP., KAR SS. Does one-to-one demonstration with insulin pads by health-care providers improves the insulin administration techniques among diabetic patients of a tertiary care teaching hospital in South India? Indian J Endocrinol Metab. 2016; 20(6):767–71.
- 33. DAVIDSON MB. Insulin therapy: a personal approach. Clin Diabetes. 2015; 33(3):123–35.
- 34. McCAMBRIDGE J., WITTON J., ELBOURNE DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol. 2014; 67(3):267–77.
- 35. RAKEL RE. Improving patient acceptance and adherence in diabetes management: a focus on insulin therapy. Adv Therapy. 2009; 26(9):838–46.
- 36. DAL-RE R., JANIAUD P., IOANNIDIS JPA. Real-world evidence: how pragmatic are randomized controlled trials labeled as pragmatic? BMC Med. 2018; 16(1):49.
- 37. ZWARENSTEIN M., TREWEEK S., GAGNIER JJ., ALTMAN DG., TUNIS S., HAYNES B, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008; 337:a2390.